Mississippi Active Pharmaceutical Ingredient Quality Assurance Act; enact to impose certain provisions for compounding.

SB 2544, the "Mississippi Active Pharmaceutical Ingredient Quality Assurance Act," sets new safety standards for pharmacies compounding custom medications (drugs mixed on-site for individual patients). It requires compounders to use bulk drug ingredients meeting U.S. Pharmacopoeia or FDA standards, verify manufacturing facility inspections, obtain certificates of analysis, and conduct quality testing before use. Pharmacies must keep related records for two years after a drug’s expiration and face penalties of $1,000 per dose sold in violation or license revocation. The bill directly affects all Mississippi pharmacies and suppliers distributing compounded drugs under federal Section 503A, aiming to ensure ingredient safety through enforceable quality controls. The bill died in committee in February 2026 and was never enacted.